ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0644

Scoping Literature Review to Identify Candidate Domains for the SLE OMERACT Core Outcome Set

Wils Nielsen1, Fadi Kharouf2, Carolina Munoz-Grajales3, Aarabi Thayaparan4, Melanie Anderson5, Lee Simon6, Maya Desai7, Ioannis Parodis8, Alfred Kim9, Yvonne Enman10, Kathleen Bingham11, Dennisse Bonilla11, Julian Thumboo12, Marta Mosca13, Martin Aringer14, Eric Morand15, Ian Bruce16, Vibeke Strand17 and Zahi Touma4, 1University of Toronto, Markham, ON, Canada, 2University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, 3UHN/TWH, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada, 5The Institute for Education Research, Library and Information Services, University Health Network, Toronto, ON, Canada, 6SDG LLC, West Newton, MA, 7Ontario College of Art and Design University, Toronto, ON, Canada, 8Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, 9Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, 10Karolinska Institutet, Stockholm, Sweden, 11University Health Network, Toronto, ON, Canada, 12Singapore General Hospital, Singapore, Singapore, 13University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, 14University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, 15School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, 16Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, 17Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA

Meeting: ACR Convergence 2024

Keywords: Measurement, OMERACT, Outcome measures, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: The Outcome Measures in Rheumatology (OMERACT) Systemic Lupus Erythematosus (SLE) Working Group was re-established in 2018 to update the SLE Core Outcome Set (COS) and includes over 260 members representing 6 continents and over 30 countries. A COS is a fundamental list of outcomes to standardize the measurement and reporting of domains/outcomes in SLE trials. The first SLE COS was developed in 1998, thus there is a need to update the SLE COS. Three years ago, the OMERACT SLE Working Group embarked on multiple projects to generate an extensive list of potential candidate domains to be included in the SLE COS. In this study, we specifically report on the scoping literature review results.

Methods: Scoping Review: We searched 5 databases (Medline, Embase, Cochrane, CINALH, PsycINFO) for SLE systematic reviews and clinical trials since 2010. 3 reviewers performed an agreement test on 100 articles for title and abstract screening using Covidence with a 98% agreement. Due to the large volume of studies, the 1st screening of title and abstract was conducted by a single reviewer. A 2nd agreement test on 100 articles was performed for full-text screening with the same reviewers with a 99% agreement. The 2nd screening of full-texts and data extraction of domain items consisted of 2 reviewers per article.

Advisory Group: An advisory group was established with OMERACT SLE Working Group Steering Committee members, Patient Research Partners, and additional SLE Expert Collaborators. This group reviewed all domain items generated from the scoping literature review, winnowing any domain items deemed too broad, narrow, multivariable, non-specific, or contextual factors, and binning the remaining domain items into preliminary candidate domains.

Results: The scoping literature review search yielded 4033 articles which title and abstract screening reduced to 605 (Figure 1). Article retrieval and full-text review further reduced the number of articles to 437. All domain items were extracted and winnowed and binned along with the results of other domain generation projects into 25 preliminary candidate domains. Related themes/domains were grouped and contextual factors were removed yielding a preliminary list of 25 domains (Table 1).

Conclusion: This scoping review identified multiple domain items expanding the list of preliminary candidate domains to 25. Future steps for SLE COS development include further generation of potential domains from qualitative research, to be followed by definition development for candidate domains in preparation for the final step in domain selection – the Delphi consensus exercise to vote on the final SLE COS.

Supporting image 1

Figure 1. PRISMA flow diagram of scoping literature review search strategy.

Supporting image 2


Disclosures: W. Nielsen: None; F. Kharouf: None; C. Munoz-Grajales: None; A. Thayaparan: None; M. Anderson: None; L. Simon: None; M. Desai: None; I. Parodis: Amgen, 5, 6, AstraZeneca, 1, 2, 6, Aurinia, 1, 5, 6, Bristol-Myers Squibb(BMS), 2, 5, Eli Lilly, 5, GlaxoSmithKlein(GSK), 1, 2, 5, 6, Janssen, 2, 6, Novartis, 1, 2, Otsuka Pharma, 1, 2, 5, 6, Roche, 2, 5, 6; A. Kim: Amgen, 2, ANI Pharmaceuticals, 2, AstraZeneca, 5, Atara Bio, 2, Aurinia Pharmaceuticals, 2, Cargo Therpeutics, 2, Exagen Diagnostics, 2, 6, GSK, 2, 5, 6, Kypha, 2, 4, 10, Miltenyi Biotech, 2, Novartis, 5, Pfizer, 2, Synthekine, 2, Techtonic Therapeutics, 2, The Rheumatology Education Group, 6; Y. Enman: None; K. Bingham: None; D. Bonilla: None; J. Thumboo: None; M. Mosca: AbbVie, 2, 6, AstraZeneca, 2, 6, GSK, 2, 5, 6, Idorsia, 2, Janssen, 6, Lilly, 6, Otsuka, 2, 6, UCB, 2; M. Aringer: GlaxoSmithKlein(GSK), 1, 6; E. Morand: AbbVie, 5, Amgen, 5, AstraZeneca, 1, 2, 5, 6, Biogen, 2, 5, Bristol Myers Squibb, 2, 5, Dragonfly, 2, Eli Lilly, 5, EMD Serono, 2, 5, Genentech, 2, 5, Gilead, 2, GSK, 2, 5, Janssen, 5, Novartis, 2, 5, RemeGen, 2, Roche, 5, 6, Takeda, 2, 5, UCB, 5, Zenas, 2; I. Bruce: AstraZeneca, GSK and UCB, 6, Genzyme/Sanofi, GSK, Roche, Novartis, Janssen, UCB, 5; V. Strand: AbbVie, 1, 2, Alpine Immune Sciences, 1, 2, Alumis, 1, 2, Amgen, 1, 2, AstraZeneca, 1, 2, Bayer, 1, 2, Blackrock Pharmaceuticals, 1, 2, Boehringer Ingelheim, 1, 2, Bristol Myers Squibb, 1, 2, Celltrion, 1, 2, Citryll, 1, 2, Contura, 1, 2, Equillium, 1, 2, Fortress Biotech, 1, 2, Genentech/Roche, 1, 2, GSK, 1, 2, Inmedix, 1, 2, Janssen, 1, 2, Kiniksa, 1, 2, Lilly, 1, 2, Novartis, 1, 2, Omeros, 1, 2, Pfizer, 1, 2, Priovant Therapeutics, 1, 2, Rapt Therapeutics, 1, 2, Regeneron, 1, 2, R-Pharm, 1, 2, Samsung, 1, 2, Sandoz, 1, 2, Sanofi, 1, 2, Scipher, 1, 2, SetPoint Medical, 1, 2, Sobi, 1, 2, Spherix, 1, 2, SynAct Pharma, 1, 2, Takeda Pharmaceuticals, 1, 2; Z. Touma: None.

To cite this abstract in AMA style:

Nielsen W, Kharouf F, Munoz-Grajales C, Thayaparan A, Anderson M, Simon L, Desai M, Parodis I, Kim A, Enman Y, Bingham K, Bonilla D, Thumboo J, Mosca M, Aringer M, Morand E, Bruce I, Strand V, Touma Z. Scoping Literature Review to Identify Candidate Domains for the SLE OMERACT Core Outcome Set [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/scoping-literature-review-to-identify-candidate-domains-for-the-sle-omeract-core-outcome-set/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/scoping-literature-review-to-identify-candidate-domains-for-the-sle-omeract-core-outcome-set/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology